(ASLN) ASLAN PHARMACEUTICALS ADR REP 5 ORD Lowers The 52 Week Low

0
10
ASLN
ASLN

ASLAN PHARMACEUTICALS ADR REP 5 ORD (ASLN)

December 6th, 2018
ASLAN PHARMACEUTICALS ADR REP 5 ORD fell $0.24 Thursday, down 4.80%, closing at $4.76. As well as the drop in value, ASLAN PHARMACEUTICALS ADR REP 5 ORD hit a new 52 week low of $4.20, breaking the previous low of $4.70 from earlier this July. ASLAN PHARMACEUTICALS ADR REP 5 ORD swung 21.43% between high and low. Despite the drop in value, trading volumes were solid at 444% of normal which can indicate investor opportunities.

Market Sectors

The market sectors were mixed Thursday with a majority of the sectors trending down. Real Estate saw the biggest increase of the day (2.66%), while Energy saw the biggest drop (1.77%). Healthcare has seen the biggest year-to-date gain at 13%. The biggest loss this year has been the Communication Services sector dropping 13%.

Communication Services saw the biggest turnaround from its 5-day performance of -0.23%, as it went up 1.04%. Energy and Materials both saw turn arounds from their five day positive performance, Energy with a drop of 1.77%.

Sector Breakdown

  • Real Estate went up with a 2.66% change.
  • Communication Services went up with a 1.04% change.
  • Consumer Discretionary went up with a 0.61% change.
  • Information Technology went up with a 0.23% change.
  • Utilities went down with a -0.10% change.
  • Consumer Staples went down with a -0.10% change.
  • Healthcare went down with a -0.31% change.
  • Industrials went down with a -0.55% change.
  • Materials went down with a -1.36% change.
  • Financials went down with a -1.44% change.
  • Energy went down with a -1.77% change.

All amounts in USD unless otherwise indicated
ASLN daily update

ASLN daily update
ASLN daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.

This site uses Akismet to reduce spam. Learn how your comment data is processed.